Dr. Ratner serves as the Chief Medical Advisor and will formulate and execute Aspira’s clinical and translational medical initiatives. She is responsible for accelerating the innovation platform and creating academic and integrated healthcare system partnerships to propel the company’s growth. She is a gynecologic oncologist specializing in ovarian malignancies at the Smilow Cancer Hospital at Yale New Haven.
As an associate professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, Dr. Ratner studies chemotherapy, targeted drug development, quality-of-life programs for patients, and early cancer detection. She is the current co-director of Discovery to Cure, director of Discovery to Cure Early Ovarian Cancer Detection program and co-founder and director of the Yale Medicine Sexual, Intimacy, and Menopause Program (SIMS), one of the country’s first programs to focus on supporting cancer survivors coping with issues that may not be discussed in other clinical settings. Dr. Ratner specializes in cytoreductive surgery for patients with advanced ovarian cancer, minimally invasive procedures (advanced laparoscopy and robotics) for patients with gynecologic malignancies or complex benign gynecologic conditions, robotic fertility sparing surgery for young patients with cancer.
Dr. Ratner is co-founder and Chief Medical officer of the MAT Organization, a non-profit established to drive early detection for ovarian cancer and to eradicate late-stage diagnosis through exhaustive education in the provider community, the first approach of this kind. She is a recipient of multiple clinical and teaching awards, most recently 2015 Yale University Smilow Cancer Center Award for Clinical Excellence. She received her education from State University of NY Medical College and did her medical residency at Yale-New Haven Hospital and her fellowship at Yale University School of Medicine.